Ekspresi Monosit Kemotatik Protein-1 (MCP-1) pada Endometriosis

(1)

Crosstabs

Kel_Usia * Subyek Crosstabulation

Subyek

Total Endometriosis

Endometrium normal

Kel_Usia <30 tahun Count 15 9 24

% within Subyek 71,4% 42,9% 57,1%

30 - 40 tahun Count 6 12 18

% within Subyek 28,6% 57,1% 42,9%

Total Count 21 21 42

% within Subyek 100,0% 100,0% 100,0%

Crosstabs

Paritas * Subyek Crosstabulation

Subyek

Total Endometriosis

Endometrium normal

Paritas 0 Count 21 4 25

% within Subyek 100,0% 19,0% 59,5%

1 - 3 Count 0 15 15

% within Subyek ,0% 71,4% 37,5%

>3 Count 0 2 2

% within Subyek ,0% 9,6% 4,8%

(2)

Crosstabs

Chi-Square Tests

Value df

Asymp. Sig. (2-sided)

Exact Sig. (2-sided)

Pearson Chi-Square 42,000a 3 ,000 ,000

Likelihood Ratio 58,224 3 ,000 ,000

Fisher's Exact Test 47,919 ,000

Linear-by-Linear Association

29,329b 1 ,000 ,000

N of Valid Cases 42

a. 4 cells (50,0%) have expected count less than 5. The minimum expected count is 1,50. b. The standardized statistic is -5,416.

Crosstabs

Proporsi dari observer 1 * Subyek Crosstabulation

Subyek

Total Endometriosis

Endometrium normal

Proporsi dari observer 1 ,00 Count 0 21 21

% within Subyek ,0% 100,0% 50,0%

1,00 Count 9 0 9

% within Subyek 42,9% ,0% 21,4%

2,00 Count 1 0 1

% within Subyek 4,8% ,0% 2,4%

3,00 Count 11 0 11

% within Subyek 52,4% ,0% 26,2%

% within Subyek 100,0% 100,0% 100,0%

(3)

Value df

28,676b 1 ,000 ,000

N of Valid Cases 42

a. 4 cells (50,0%) have expected count less than 5. The minimum expected count is ,50. b. The standardized statistic is -5,355.

Proporsi dari observer 1 * Proporsi dari obsrever 2 Crosstabulation

Proporsi dari obsrever 2

Total

,00 1,00 2,00 3,00

Proporsi dari observer 1 ,00 Count 21 0 0 0 21

% within Proporsi dari obsrever 2

100,0% ,0% ,0% ,0% 50,0%

1,00 Count 0 7 2 0 9

,0% 100,0% 40,0% ,0% 21,4%

2,00 Count 0 0 1 0 1

,0% ,0% 20,0% ,0% 2,4%

3,00 Count 0 0 2 9 11

,0% ,0% 40,0% 100,0% 26,2%

Total Count 21 7 5 9 42

(4)

Symmetric Measures

Value

Asymp. Std.

Errora Approx. Tb Approx. Sig.

Measure of Agreement Kappa ,855 ,065 8,734 ,000

N of Valid Cases 42

a. Not assuming the null hypothesis.

b. Using the asymptotic standard error assuming the null hypothesis.

Stadium * Proporsi dari observer 1 Crosstabulation

Proporsi dari observer 1

Total

1,00 2,00 3,00

Stadium 2,00 Count 0 0 2 2

% within Proporsi dari observer 1

,0% ,0% 18,2% 9,5%

3,00 Count 5 0 3 8

55,6% ,0% 27,3% 38,1%

4,00 Count 4 1 6 11

44,4% 100,0% 54,5% 52,4%

Total Count 9 1 11 21

100,0% 100,0% 100,0% 100,0%

Value df

Exact Sig.

(1-sided) Point Probability

,081b 1 ,776 ,904 ,472 ,156

N of Valid Cases 21

a. 8 cells (88,9%) have expected count less than 5. The minimum expected count is ,10. b. The standardized statistic is -,285.

(5)

HasilPemeriksaan MCP-1

No Nama No lab PA Usia Paritas DerajatNyeri Stad Endometriosis

HistopatologiJaringan EkspresiMCP1 Intensity score

Observer 1

Ekspresi MCP1 Intensity score

Observer 2 1 Ny N R/HS/03/13 31thn P0A0 Ringan 3 Kista Endometriosis +2 +2 2 Ny A R/HS/04/13 27 thn P0A0 Sedang 3 Kista Endometriosis +2 +2 3 Ny E R/HS/07/13 35thn P0A0 Sedang 4 Kista Endometriosis +2 +3 4 Ny I R/HS/09/13 32thn P0A0 Sedang 3 Endometriosis +1 +1 5 Ny S R/HS/12/13 20 thn P0A0 Ringan 3 Endometriosis +1 +1 6 Ny R R/HS/18/13 35thn P0A0 Ringan 4 Endometriosis +1 +1 7 Ny J R/HS/21/13 27thn P0A0 Sedang 4 Kista Endometriosis +2 +3 8 Ny W R/HS/23/13 20thn P0A0 Sedang 3 Kista Endometriosis +1 +1 9 Ny H R/HS/25/13 28thn P0A0 Sedang 4 Kista Endometriosis +1 +1 10 Ny N R/HS/29/13 26thn P0A0 Sedang 4 Kista Endometriosis +3 +3 11 Ny L R/HS/33/13 24thn P0A0 Sedang 3 Kista Endometriosis +1 +1 12 Ny J R/HS/61/13 26 thn P0A0 Sedang 4 Kista Endometriosis +1 +2 13 Ny Y R/HS/62/13 27 thn P0A0 Berat 3 Kista Endometriosis +1 +1 14 Ny B R/HS/63/13 29 thn P0A0 Sedang 4 Kista Endometriosis +1 +1 15 Ny D R/HS/64/13 39 thn P0A0 Ringan 2 Kista Endometriosis +2 +2 16 Ny A R/HS/65/13 24 thn P0A0 Sedang 4 Kista Endometriosis +3 +3 17 Ny E R/HS/66/13 33 thn P0A0 Sedang 3 Kista Endometriosis +1 +1 18 Ny S R/HS/67/13 25 thn P0A0 Sedang 4 Kista Endometriosis +3 +3 19 Ny E R/HS/74/13 29 thn P0A0 Sedang 4 Kista Endometriosis +1 +1 20 Ny I R/HS/83/13 29 thn P0A0 Sedang 4 Endometriosis +2 +2 21 Ny N R/HS/96/13 19 thn P0A0 Sedang 2 Kista Endometriosis +2 +2

LaboratoriumPatologiAnatomi FK USU

diketahui

(6)

No Nama No lab PA Usia Paritas DerajatNyeri Stad Endometriosis

HistopatologiJaringan Ekspresi MCP1 Proportion Observer 1

Ekspresi MCP1 Proportion Observer 2 1 Ny N R/HS/03/13 31 thn P0A0 Ringan 3 Kista Endometriosis +3 +3 2 Ny A R/HS/04/13 27 thn P0A0 Sedang 3 Kista Endometriosis +3 +2 3 Ny E R/HS/07/13 35 thn P0A0 Sedang 4 Kista Endometriosis +2 +3 4 Ny I R/HS/09/13 32 thn P0A0 Sedang 3 Endometriosis +2 +1 5 Ny S R/HS/12/13 20 thn P0A0 Ringan 3 Endometriosis +1 +1 6 Ny R R/HS/18/13 35 thn P0A0 Ringan 4 Endometriosis +1 +2 7 Ny J R/HS/21/13 27 thn P0A0 Sedang 4 Kista Endometriosis +3 +3 8 Ny W R/HS/23/13 20 thn P0A0 Sedang 3 Kista Endometriosis +1 +1 9 Ny H R/HS/25/13 28 thn P0A0 Sedang 4 Kista Endometriosis +1 +1 10 Ny N R/HS/29/13 26 thn P0A0 Sedang 4 Kista Endometriosis +2 +2 11 Ny L R/HS/33/13 24 thn P0A0 Sedang 3 Kista Endometriosis +1 +3 12 Ny J R/HS/61/13 26 thn P0A0 Sedang 4 Kista Endometriosis +1 +1 13 Ny Y R/HS/62/13 27 thn P0A0 Berat 3 Kista Endometriosis +1 +2 14 Ny B R/HS/63/13 29 thn P0A0 Sedang 4 Kista Endometriosis +2 +3 15 Ny D R/HS/64/13 39 thn P0A0 Ringan 2 Kista Endometriosis +2 +3 16 Ny A R/HS/65/13 24 thn P0A0 Sedang 4 Kista Endometriosis +3 +3 17 Ny E R/HS/66/13 33 thn P0A0 Sedang 3 Kista Endometriosis +1 +1 18 Ny S R/HS/67/13 25 thn P0A0 Sedang 4 Kista Endometriosis +3 +3 19 Ny E R/HS/74/13 29 thn P0A0 Sedang 4 Kista Endometriosis +1 +1 20 Ny I R/HS/83/13 29 thn P0A0 Sedang 4 Endometriosis +3 +2 21 Ny N R/HS/96/13 19 thn P0A0 Sedang 2 Kista Endometriosis +3 +3

LaboratoriumPatologiAnatomi FK USU

diketahui

( drJessyChrestella, SpPA )

HasilPemeriksaan MCP-1

(7)

Endometriosis Jaringan Intensity score Observer 1

Intensity score Observer 2

1 Ny R O/HG/1/13 29 thn P3A0 Endometrium Negatif Negatif

2 Ny E O/HG/2/13 30 thn P1A0 Endometrium Negatif Negatif

4 Ny P O/HG/5/13 29 thn P2A0 Endometrium Negatif Negatif

6 Ny S O/HG/8/13 30 thn P1A1 Endometrium Negatif Negatif

10 Ny M O/HG/13/13 30 thn P4A0 Endometrium Negatif Negatif

11 Ny N O/HG/14/13 32 thn P2A1 Endometrium Negatif Negatif

12 Ny I O/HG/16/13 32 thn P1A0 Endometrium Negatif Negatif

13 Ny D O/HG/20/13 28 thn P3A2 Endometrium Negatif Negatif

14 Ny D O/HG/21/13 27 thn P1A0 Endometrium Negatif Negatif

15 Ny F O/HG/22/13 31 thn P2A0 Endometrium Negatif Negatif

18 Ny A O/HG/32/13 28 thn P0A0 Endometrium Negatif Negatif

20 Ny P O/HG/42/13 34 thn P0A0 Endometrium Negatif Negatif

LaboratoriumPatologiAnatomi FK USU

diketahui

( drJessyChrestella, SpPA )

(8)

1 Ny R O/HG/1/13 29 thn P3A0 Endometrium 0 0

2 Ny E O/HG/2/13 30 thn P1A0 Endometrium 0 0

4 Ny P O/HG/5/13 29 thn P2A0 Endometrium 0 0

6 Ny S O/HG/8/13 30 thn P1A1 Endometrium 0 0

10 Ny M O/HG/13/13 30 thn P4A0 Endometrium 0 0

11 Ny N O/HG/14/13 32 thn P2A1 Endometrium 0 0

12 Ny I O/HG/16/13 32 thn P1A0 Endometrium 0 0

13 Ny D O/HG/20/13 28 thn P3A2 Endometrium 0 0

14 Ny D O/HG/21/13 27 thn P1A0 Endometrium 0 0

15 Ny F O/HG/22/13 31 thn P2A0 Endometrium 0 0

18 Ny A O/HG/32/13 28 thn P0A0 Endometrium 0 0

20 Ny P O/HG/42/13 34 thn P0A0 Endometrium 0 0

LaboratoriumPatologiAnatomi FK USU

diketahui

( drJessyChrestella, SpPA )

(9)

SANTA CRUZ BIOTECHNOLOGY, INC.

MCP-1 (5J): sc-32771

BACKGROUND

The monocyte chemotactic proteins, MCP-1, MCP-2 and MCP-3, form a sub-family of the C-C (orβ) chemokines, which are characterized by a set of con-served adjacent cysteines. MCPs are produced by a variety of cells, including T lymphocytes, subsequent to their activation with cytokines such as IL-1, TNFαand IFN-γ. MCP-1 levels are increased during infection and inflamma-tion, which are both characterized by leukocyte infiltration.In vitro_studies have shown that the MCP isoforms exhibit their chemotactic effects on dif-ferent subpopulations of lymphocytes. MCP-1 is a potent basophil activator but does not affect eosinophils, whereas MCP-2 stimulates both eosinophils and basophils. MCP-3 has been shown to have the broadest range of influ-ence, activating monocytes, dendritic cells, lymphocytes, natural killer cells, eosinophils, basophils and neutrophils. Two MCP-1 receptors that differ in their carboxy-termini have been identified.

REFERENCES

1. Charo, I.F., et al. 1994. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. USA 91: 2752-2756.

2. Taub, D.D., et al. 1995. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J. Clin. Invest. 95: 1370-1376.

3. Weber, M., et al. 1995. Monocyte chemotactic protein MCP-2 activates human basophil and eosinophil leukocytes similar to MCP-3. J. Immunol. 154: 4166-4172.

4. Combadiere, C., et al. 1995. Monocyte chemoattractant protein-3 is a functional ligand for C-C chemokine receptors 1 and 2B. J. Biol. Chem. 270: 29671-29675.

5. Proost, P., et al. 1996. Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J. Leukoc. Biol. 59: 67-74.

6. Dubois, P.M., et al. 1996. Early signal transduction by the receptor to the chemokine monocyte chemotactic protein-1 in a murine T cell hybrid. J. Immunol. 156: 1356-1361.

7. Beall, C.J., et al. 1996. Site-directed mutagenesis of monocyte chemo-attractant protein-1 identifies two regions of the polypeptide essential for biological activity. Biochem. J. 313: 633-640.

8. Kuna, P., et al. 1996. Chemokines in seasonal allergic rhinitis. J. Allergy Clin. Immunol. 97: 104-112.

CHROMOSOMAL LOCATION

Genetic locus: CCL2 (human) mapping to 17q12.

SOURCE

MCP-1 (5J) is a mouse monoclonal antibody raised against recombinant MCP-1 of human origin.

STOR AGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PRODUCT

Each vial contains 200 µg IgG₁in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Available azide-free for neutralizing, sc-32771 L, 200 µg/0.1 ml.

APPLICATIONS

MCP-1 (5J) is recommended for detection of MCP-1 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500).

Suitable for use as control antibody for MCP-1 siRNA (h): sc-43913, MCP-1 shRNA Plasmid (h): sc-43913-SH and MCP-1 shRNA (h) Lentiviral Particles: sc-43913-V.

Molecular Weight of MCP-1: 12 kDa.

Positive Controls: human PBL whole cell lysate.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-mouse IgG-HRP: sc-2005 (dilution range: 1:2000-1:32,000) or Cruz Marker™ compatible goat anti-mouse IgG-HRP: sc-2031 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecip-itation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use goat anti-mouse IgG-FITC: sc-2010 (dilution range: 1:100-1:400) or goat anti-mouse IgG-TR: sc-2781 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941. 4) Immuno-histochemistry: use ImmunoCruz™: sc-2050 or ABC: sc-2017 mouse IgG Staining Systems.

DATA

RESEARCH USE

For research use only, not for use in diagnostic procedures. MCP-1 (5J): sc-32771. Western blot analysis of human

recombinant MCP-1.